Galapagos Pledges More Restraint On Pipeline Potential

But Keeping The Faith With Toledo

19 Jul 2021

The Belgium-headquartered firm has struggled of late to impress investors, most recently with data from its salt-inducible kinase inhibitors, and CMO Walid Abi-Saab told Scrip that one reason could be "the level of optimism that prevails in the company. We jump on things a bit ahead of time."

Galapagos hoping for no more false starts with its pipeline • Source: Alamy

Having presented underwhelming initial data from its closely watched Toledo program, Galapagos NV's chief medical officer has told Scrip that the Belgian biotech had been too eager to talk up the potential of its salt-inducible kinase (SIK) inhibitors in the past but insists that the results represent "unequivocal evidence of clinical efficacy in inflammatory diseases."

Walid Abi-Saab was speaking after the company's stock took a battering after the first data were presented on GLPG3970, a...